VivoSim Labs Balance Sheet

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Cash & Equivalents	5.02	11.31	2.9	15.3	28.68
Short-Term Investments	-	-	-	0.71	-
Cash & Short-Term Investments	5.02	11.31	2.9	16.01	28.68
Cash Growth	-55.59%	289.94%	-81.88%	-44.18%	-23.25%
Accounts Receivable	0.03	0.03	0.03	0.15	-
Other Receivables	1.01	-	-	-	-
Total Trade Receivables	1.05	0.03	0.03	0.15	-
Inventory	-	-	0.3	-	-
Other Current Assets	0.56	0.79	0.71	0.89	0.86
Total Current Assets	6.63	12.13	3.94	17.05	29.53
Net Property, Plant & Equipment	0.61	1.29	1.97	2.61	2.82
Other Long-Term Assets	0.15	1.23	0.45	0.66	0.95
Total Assets	7.39	14.65	6.35	20.31	33.3
Accounts Payable	1.02	1.64	0.63	0.33	0.42
Accrued Expenses	0.98	1.23	0.73	2.85	0.49
Short-Term Debt	0.12	0.13	-	-	-
Current Portion of Leases	0.45	0.52	0.51	0.49	0.48
Other Current Liabilities	0.22	0.22	-	-	-
Total Current Liabilities	2.79	3.74	1.86	3.67	1.38
Long-Term Leases	-	0.42	0.89	1.31	1.7
Other Long-Term Liabilities	5.7	-	-	-	-
Total Long-Term Liabilities	5.7	0.42	0.89	1.31	1.7
Total Liabilities	8.49	4.16	2.75	4.98	3.09
Common Stock	0	0	0	0.01	0.01
Treasury Stock	-	-0	-0	-0	-0
Additional Paid-in Capital	354.9	352.65	343.27	340.32	337.94
Accumulated Other Comprehensive Income	-	-	-	0	-
Retained Earnings	-356	-342.16	-339.67	-325	-307.74
Shareholders' Equity	-1.1	10.49	3.6	15.33	30.21
Total Liabilities & Equity	7.39	14.65	6.35	20.31	33.3
Total Debt	0.57	1.07	1.39	1.81	2.18
Net Cash (Debt)	4.46	10.24	1.51	14.2	26.49
Net Cash Growth	-56.46%	579.63%	-89.39%	-46.39%	-29.10%
Net Cash Per Share	1.72	7.00	1.98	19.56	36.53
Book Value	-1.1	10.49	3.6	15.33	30.21
Book Value Per Share	-0.42	7.17	4.73	21.11	41.65
Tangible Book Value	-1.1	10.49	3.6	15.33	30.21
Tangible Book Value Per Share	-0.42	7.17	4.73	21.11	41.65

SEC Filings: 10-K · 10-Q